SCHEDULE 13G/A: Vanguard Group Amends Passive Stake in OptimizeRx Corp to 4.98%

The Vanguard Group has filed an Amendment No. 3 to its Schedule 13G, disclosing a 4.98% passive beneficial ownership in OptimizeRx Corp's Common Stock as of March 31, 2025.

Summary

• The Vanguard Group, an investment adviser, filed an Amendment No. 3 to Schedule 13G regarding its beneficial ownership in OptimizeRx Corp.
• As of March 31, 2025, Vanguard beneficially owns 921,848 shares of OptimizeRx Corp's Common Stock.
• This ownership represents 4.98% of the class of securities.
• Vanguard holds sole dispositive power over 897,962 shares and shared dispositive power over 23,886 shares.
• Vanguard holds shared voting power over 16,989 shares and no sole voting power.
• The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 6

Explanation: The filing is largely neutral as it's a routine ownership disclosure. However, the presence of a significant, albeit passive, stake by a major institutional investor like Vanguard can be interpreted as a minor positive signal of market confidence.

Positives

• The disclosure of a significant, albeit passive, ownership stake by a major institutional investor like The Vanguard Group can be viewed as a positive signal of confidence in OptimizeRx Corp.

Future Outlook

NA

Industry Context

This filing is a routine disclosure of institutional ownership, common in the financial industry. It reflects The Vanguard Group's passive investment strategy across various public companies, including those in the healthcare technology sector like OptimizeRx Corp.

Stakeholder Impact

• Shareholders: Provides transparency on institutional ownership, indicating a major asset manager's passive stake in the company.

Key Dates

Recommendation

Keywords

OptimizeRx Corp, Vanguard Group, Schedule 13G, Common Stock, Beneficial Ownership, Institutional Investor, Passive Investment, SEC Filing